Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca 2+ handling
Autor: | Tatiana Romero-Garcia, José Alberto Navarro-García, Carlos Zaragoza, María Fernández-Velasco, Makoto Kuro-o, Gema Ruiz-Hurtado, Elena Rodríguez-Sánchez, Angélica Rueda, Jennifer Aceves-Ripoll, Laura González-Lafuente, Luis M. Ruilope |
---|---|
Rok vydání: | 2020 |
Předmět: |
Ryanodine receptors
0301 basic medicine Genetically modified mouse medicine.medical_specialty Farmacología Transgene Terapéutica Cardiomyopathy Context (language use) Cardiología urologic and male genital diseases Klotho Tratamiento médico 03 medical and health sciences 0302 clinical medicine Chronic kidney disease Ca2+/calmodulin-dependent protein kinase Internal medicine Ca2+ mishandling medicine Protein kinase A Sistema cardiovascular Pharmacology Chemistry Ryanodine receptor medicine.disease female genital diseases and pregnancy complications 030104 developmental biology Endocrinology Uraemic cardiomyopathy 030217 neurology & neurosurgery |
Zdroj: | DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria instname DDFV: Repositorio Institucional de la Universidad Francisco de Vitoria Universidad Francisco de Vitoria |
ISSN: | 1476-5381 0007-1188 |
DOI: | 10.1111/bph.15235 |
Popis: | Background and Purpose Klotho is a membrane‐bound or soluble protein, originally identified as an age‐suppressing factor and regulator of mineral metabolism. Klotho deficiency is associated with the development of renal disease, but its role in cardiac function in the context of uraemic cardiomyopathy is unknown. Experimental Approach We explored the effects of Klotho on cardiac Ca2+ cycling. We analysed Ca2+ handling in adult cardiomyocytes from Klotho‐deficient (kl/kl) mice and from a murine model of 5/6 nephrectomy (Nfx). We also studied the effect of exogenous Klotho supplementation, by chronic recombinant Klotho treatment, or endogenous Klotho overexpression, using transgenic mice overexpressing Klotho (Tg‐Kl), on uraemic cardiomyopathy. Hearts from Nfx mice were used to study Ca2+ sensitivity of ryanodine receptors and their phosphorylation state. Key Results Cardiomyocytes from kl/kl mice showed decreased amplitude of intracellular Ca2+ transients and cellular shortening together with an increase in pro‐arrhythmic Ca2+ events compared with cells from wild‐type mice. Cardiomyocytes from Nfx mice exhibited the same impairment in Ca2+ cycling as kl/kl mice. Changes in Nfx cardiomyocytes were explained by higher sensitivity of ryanodine receptors to Ca2+ and their increased phosphorylation at the calmodulin kinase type II and protein kinase A sites. Ca2+ mishandling in Nfx‐treated mice was fully prevented by chronic recombinant Klotho administration or transgenic Klotho overexpression. Conclusions and Implications Klotho emerges as an attractive therapeutic tool to improve cardiac Ca2+ mishandling observed in uraemic cardiomyopathy. Strategies that improve Klotho availability are good candidates to protect the heart from functional cardiac alterations in renal disease. Sin financiación 8.740 JCR (2020) Q1, 12/276 Pharmacology & Pharmacy 2.432 SJR (2020) Q1, 16/314 Pharmacology No data IDR 2020 UEM |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |
načítá se...